# EDGAR Filing Document

**Accession Number:** 0001609805
**File Stem:** 0001437749-23-004870
**Filing Date:** 2023-2
**Character Count:** 6005
**Document Hash:** 46a129392ce7afd3cbe6acd4148b3fc9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-004870.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0001437749-23-004870

**CONFORMED SUBMISSION TYPE**: 4/A

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20220606

**FILED AS OF DATE**: 20230228

**DATE AS OF CHANGE**: 20230228

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Nussbaum Ran
- **CENTRAL INDEX KEY:** 0001609805

**FILING VALUES:**
- **FORM TYPE:** 4/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38079
- **FILM NUMBER:** 23681928

**MAIL ADDRESS:**
- **STREET 1:** C/O KITE PHARMA, INC.
- **STREET 2:** 2225 COLORADO AVENUE
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90404
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** UroGen Pharma Ltd.
- **CENTRAL INDEX KEY:** 0001668243
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 9 HA'TA'ASIYA ST
- **CITY:** RA'ANANA
- **STATE:** L3
- **ZIP:** 4365007
- **BUSINESS PHONE:** 972 9 770 7601

**MAIL ADDRESS:**
- **STREET 1:** 9 HA'TA'ASIYA ST
- **CITY:** RA'ANANA
- **STATE:** L3
- **ZIP:** 4365007

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4/A

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Nussbaum Ran<br><sub>(Last) (First) (Middle)</sub><br>400 ALEXANDER PARK DRIVE<br><sub>(Street)</sub><br>PRINCETON, NJ 08540<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-06-06 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>UroGen Pharma Ltd. [ URGN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2022-06-06 |  | M |  | 1030 | A | $5 | 1434958<sup>(1)</sup> | I | Managing member of entities affiliated with Pontifax Management III G.P. <sup>(2011)</sup> Ltd. |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $5 | 2022-06-06 |  | M |  |  | 1030 | 2015-09-01 | 2022-09-01<sup>(2)</sup> | Ordinary Shares | 1030 | $0 | 0 | I | By Pontifax Cayman III Limited Partnership |

---

### Footnotes:

(1) On August 25, 2022, the reporting person filed a Form 4 that inadvertently reported 1,433,928 shares of securities beneficially owned following reported transaction instead of 1,434,958 shares.

(2) On August 25, 2022, the reporting person filed a Form 4 that inadvertently list the expiration date as August 31, 2022.

**Signature:** /s/ Jason D. Smith, Attorney-in-Fact  
**Date:** 2023-02-28

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**